title: Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of intravitreal injections of bevacizumab as an eye-sparing treatment for iris neovascularization (NVI) following proton beam irradiation for choroidal melanoma.
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  Four patients who received intravitreal bevacizumab for NVI following proton beam irradiation for choroidal melanoma were identified in the Department of Ophthalmology archives at the University of British Columbia.
  
  
  METHODS
  Clinical details were reviewed. Long-term follow-up of more than 2 years was detailed for each case.
  
  
  RESULTS
  All 4 patients responded to a single injection of bevacizumab with regression of NVI. Neovascular glaucoma (NVG) was evident in 3 cases, 2 of which had stable intraocular pressure following treatment. NVI recurred following a single injection in all patients after an interval ranging from 1 month to 12 months. A longer period of regression was seen in patients with fewer systemic neovascular risk factors and earlier treatment.
  
  
  CONCLUSIONS
  Regression of NVI following proton beam irradiation for choroidal melanoma was seen in all treated patients. Repeated treatments may be required to maintain regression of new vessels. This treatment modality may be a useful eye-sparing adjunct in the prevention and treatment of NVG following proton beam irradiation.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Eye Care Centre, Vancouver Hospital, University of British Columbia, Vancouver, B.C. sonia.y@gmail.com
authors.forename: Sonia N
authors.initials: SN
authors.lastname: Yeung
authors.forename: Katherine E
authors.initials: KE
authors.lastname: Paton
authors.forename: Christopher
authors.initials: C
authors.lastname: Waite
authors.forename: David A
authors.initials: DA
authors.lastname: Maberley
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D015355:Glaucoma, Neovascular / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply / Q000528:radiation effects*; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D011522:Protons; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011522:Protons; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab